(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Oric Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ORIC's revenue for 2026 to be $201,890,147, with the lowest ORIC revenue forecast at $201,890,147, and the highest ORIC revenue forecast at $201,890,147. On average, 2 Wall Street analysts forecast ORIC's revenue for 2028 to be $2,108,472,453, with the lowest ORIC revenue forecast at $1,080,538,816, and the highest ORIC revenue forecast at $3,136,406,090.
In 2029, ORIC is forecast to generate $6,510,246,366 in revenue, with the lowest revenue forecast at $6,510,246,366 and the highest revenue forecast at $6,510,246,366.